LV10190B - Method for treating alcoholism with nalmefene - Google Patents

Method for treating alcoholism with nalmefene Download PDF

Info

Publication number
LV10190B
LV10190B LVP-93-1052A LV931052A LV10190B LV 10190 B LV10190 B LV 10190B LV 931052 A LV931052 A LV 931052A LV 10190 B LV10190 B LV 10190B
Authority
LV
Latvia
Prior art keywords
alcohol
nalmefene
drinking
extinction
patient
Prior art date
Application number
LVP-93-1052A
Other languages
English (en)
Latvian (lv)
Other versions
LV10190A (lv
Inventor
John D Sinclair
Scheinin Harry
Lammintausta Risto
Original Assignee
Alko Ltd
Orion Yhtymae Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alko Ltd, Orion Yhtymae Oy filed Critical Alko Ltd
Publication of LV10190A publication Critical patent/LV10190A/xx
Publication of LV10190B publication Critical patent/LV10190B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
LVP-93-1052A 1990-06-04 1993-08-31 Method for treating alcoholism with nalmefene LV10190B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/532,424 US5086058A (en) 1990-06-04 1990-06-04 Method for treating alcoholism with nalmefene
PCT/US1991/003241 WO1991018605A1 (en) 1990-06-04 1991-05-10 Method for treating alcoholism with nalmefene

Publications (2)

Publication Number Publication Date
LV10190A LV10190A (lv) 1994-10-20
LV10190B true LV10190B (en) 1995-06-20

Family

ID=24121726

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-93-1052A LV10190B (en) 1990-06-04 1993-08-31 Method for treating alcoholism with nalmefene

Country Status (19)

Country Link
US (1) US5086058A (lt)
EP (1) EP0531415B1 (lt)
JP (1) JP3059213B2 (lt)
AT (1) ATE145329T1 (lt)
AU (1) AU642748B2 (lt)
CA (1) CA2084519C (lt)
DE (1) DE69123247T2 (lt)
DK (1) DK0531415T3 (lt)
ES (1) ES2097209T3 (lt)
FI (1) FI925513A (lt)
GR (1) GR3022289T3 (lt)
HU (1) HU210637B (lt)
IE (1) IE77333B1 (lt)
LT (1) LT3893B (lt)
LV (1) LV10190B (lt)
NZ (1) NZ238391A (lt)
RU (1) RU2090190C1 (lt)
WO (1) WO1991018605A1 (lt)
ZA (1) ZA914185B (lt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US6271239B1 (en) * 1992-04-13 2001-08-07 Regents Of The University Of Minnesota Delta opioid receptor-selective benzylidene-substituted morphinans
US5352680A (en) * 1992-07-15 1994-10-04 Regents Of The University Of Minnesota Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
USRE36547E (en) * 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US5298622A (en) * 1993-05-12 1994-03-29 Regents Of The University Of Minnesota Spiroindane opiate analogs
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
US5587381A (en) * 1995-03-27 1996-12-24 Sinclair; John D. Method for terminating methadone maintenance through extinction of the opiate-taking responses
WO1997018781A1 (en) * 1995-11-20 1997-05-29 University Of Miami Method of treating nicotine dependence
US5878750A (en) * 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
US5780479A (en) * 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
JP2001526229A (ja) 1997-12-22 2001-12-18 ユーロ−セルティーク，エス．エイ． オピオイド投薬剤形の乱用を防止する方法
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
HU1500214D0 (hu) 1997-12-22 2002-03-28 Euro Celtique Sa Opioid agonista és antagonista hatóanyagot tartalmazó gyógyszerkészítmény
EP1248800A2 (en) * 1999-11-30 2002-10-16 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
OA12215A (en) 2000-02-08 2006-05-09 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations.
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US20040024004A1 (en) * 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
US6528520B2 (en) * 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6262062B1 (en) * 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
ES2361148T3 (es) 2001-05-11 2011-06-14 Endo Pharmaceuticals Inc. Forma de dosificación de opioides de liberación controlada resistente al abuso.
ATE540613T1 (de) * 2001-07-13 2012-01-15 Arkray Inc Analysevorrichtung und durchstechelement- integrierte verbindung für eine konzentrationsanalysevorrichtung
DE60230632D1 (de) * 2001-07-18 2009-02-12 Euro Celtique Sa Pharmazeutische kombinationen von oxycodon und naloxon
IS7142A (is) 2001-08-06 2004-02-05 Euroceltique S.A. Lyfjasamsetningar, sem innihalda morfíngerandaefni, ásamt losanlegu en hömdu mótlyfi
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
AU2002324624A1 (en) * 2001-08-06 2003-02-24 Euro-Celtique S.A. Sequestered antagonist formulations
JP2005508888A (ja) * 2001-08-14 2005-04-07 バイオティ セラピーズ コーポレイション アルコール依存症またはアルコール中毒を治療する方法
EP2425823A1 (en) 2002-04-05 2012-03-07 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
US7501433B2 (en) * 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US7923454B2 (en) * 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
PT2561860T (pt) * 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
EP1551372B8 (en) * 2002-09-20 2018-08-01 Alpharma Pharmaceuticals LLC Sequestering subunit and related compositions and methods
EP1610791B1 (en) * 2003-03-31 2011-02-23 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
AU2004229551A1 (en) * 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
US8017622B2 (en) 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1702558A1 (en) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP2526932B1 (en) 2006-06-19 2017-06-07 Alpharma Pharmaceuticals LLC Pharmaceutical composition
SI2724722T1 (sl) 2006-10-20 2017-07-31 Neurendo Pharma, Llc Postopek za obnovitev učinka inkretina
US20100266645A1 (en) * 2007-12-17 2010-10-21 Alfred Liang Pharmaceutical compositions
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
ATE523512T1 (de) * 2008-04-24 2011-09-15 Janssen Pharmaceutica Nv Nalmefen-prodrugs
KR101598138B1 (ko) * 2008-04-24 2016-02-29 얀센 파마슈티카 엔.브이. 날메펜 디에스테르 프로드럭
EP2317991B1 (en) * 2008-07-07 2017-05-03 Euro-Celtique S.A. Use of opioid antagonists for treating urinary retention
MX347106B (es) 2009-03-10 2017-04-12 Euro-Celtique S A * Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona.
US20140005217A1 (en) * 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
WO2014170353A1 (en) * 2013-04-17 2014-10-23 H. Lundbeck A/S Nalmefene for treatment of patients with sleep disorder
CN105517551A (zh) 2013-07-23 2016-04-20 欧洲凯尔特公司 用于在患有疼痛和导致肠生态失调和/或提高肠细菌移位风险之疾病的患者中治疗疼痛的羟考酮与纳洛酮的组合
US20170042887A1 (en) * 2014-04-22 2017-02-16 Otsuka Pharmaceutical. Co., Ltd. Combination of Brexpiprazole and Nalmefene and Use Thereof for Treating Substance-Related Disorders
EP3215154B1 (en) 2014-11-07 2020-01-29 Regents of the University of Minnesota Salts and compositions useful for treating disease
EP3445363A1 (en) * 2016-04-22 2019-02-27 Taiwanj Pharmaceuticals Co., Ltd. Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US4857533A (en) * 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
US5096715A (en) * 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist

Also Published As

Publication number Publication date
HU210637B (en) 1995-06-28
FI925513A0 (fi) 1992-12-04
JPH06506665A (ja) 1994-07-28
FI925513A (fi) 1992-12-04
GR3022289T3 (en) 1997-04-30
NZ238391A (en) 1997-06-24
HU9203835D0 (en) 1993-03-29
IE911888A1 (en) 1991-12-04
CA2084519C (en) 1999-02-09
EP0531415B1 (en) 1996-11-20
WO1991018605A1 (en) 1991-12-12
EP0531415A1 (en) 1993-03-17
LT3893B (en) 1996-04-25
LTIP1486A (en) 1995-09-25
AU642748B2 (en) 1993-10-28
JP3059213B2 (ja) 2000-07-04
ZA914185B (en) 1992-07-29
HUT65523A (en) 1994-06-28
AU7974091A (en) 1991-12-31
ES2097209T3 (es) 1997-04-01
IE77333B1 (en) 1997-12-03
RU2090190C1 (ru) 1997-09-20
CA2084519A1 (en) 1991-12-05
LV10190A (lv) 1994-10-20
ATE145329T1 (de) 1996-12-15
DE69123247D1 (de) 1997-01-02
DE69123247T2 (de) 1998-01-15
US5086058A (en) 1992-02-04
DK0531415T3 (da) 1996-12-09

Similar Documents

Publication Publication Date Title
EP0531415B1 (en) Method for treating alcoholism with nalmefene
US4882335A (en) Method for treating alcohol-drinking response
Bem et al. Dextromethorphan: an overview of safety issues
Sandman The opiate hypothesis in autism and self-injury
Woolverton et al. The effects of a D1 and a D2 dopamine antagonist on behavior maintained by cocaine or food
Martin et al. Methadone—a reevaluation
Charney et al. Clonidine and naltrexone: a safe, effective, and rapid treatment of abrupt withdrawal from methadone therapy
Stapleton et al. Naloxone reduces fluid consumption in water-deprived and nondeprived rats
EP1681057B1 (en) Use of naloxone for treating eating disorders
JPH11505547A (ja) ナルトレキソン及び関連化合物を用いる禁煙処置
EP0563336B1 (en) Pharmaceutical composition containing gamma-hydroxybutyric acid or its lactone in the treatment of drug dependence and nutritional disorders
DE112006001234T5 (de) Verfahren und Zusammensetzung zur Behandlung von ARG
Hubbell et al. Opioids modulate rats’ intakes of alcoholic beverages
Goetting et al. Systemic atropine administration during cardiac arrest does not cause fixed and dilated pupils
US5587381A (en) Method for terminating methadone maintenance through extinction of the opiate-taking responses
US5140032A (en) Drug therapy for alcohol abusers
EP3454853B1 (en) Treatment of alcoholism and depression using ibudilast
Milne et al. Naloxone: New therapeutic roles
CA2429801A1 (en) Behavior chemotherapy
US5543407A (en) Preparation and application of scopolamine and chlorpromazine as a drug-withdrawal agent
Nagain‐Domaine et al. Modulation by alcohol and methadone of 2‐deoxyglucose‐stimulated pancreatic secretion in the rat
Cleary et al. Effects of imipramine on responding reduced by methadone
Reid et al. Research with rats germane to medication for alcoholism: Consequences of noncompliance
Doty et al. Effects of Naltrexone Pretreatment on Acute Responses to Ethanol in Social Drinkers
Hollandsworth et al. Psychoactive Substance Use Disorders